23
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Prognostic role of computed tomography analysis using deep learning algorithm in patients with chronic hepatitis B viral infection

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Background/Aims

          The prediction of clinical outcomes in patients with chronic hepatitis B (CHB) is paramount for effective management. This study aimed to evaluate the prognostic value of computed tomography (CT) analysis using deep learning algorithms in patients with CHB.

          Methods

          This retrospective study included 2,169 patients with CHB without hepatic decompensation who underwent contrast-enhanced abdominal CT for hepatocellular carcinoma (HCC) surveillance between January 2005 and June 2016. Liver and spleen volumes and body composition measurements including subcutaneous adipose tissue (SAT), visceral adipose tissue (VAT), and skeletal muscle indices were acquired from CT images using deep learning-based fully automated organ segmentation algorithms. We assessed the significant predictors of HCC, hepatic decompensation, diabetes mellitus (DM), and overall survival (OS) using Cox proportional hazard analyses.

          Results

          During a median follow-up period of 103.0 months, HCC (n=134, 6.2%), hepatic decompensation (n=103, 4.7%), DM (n=432, 19.9%), and death (n=120, 5.5%) occurred. According to the multivariate analysis, standardized spleen volume significantly predicted HCC development (hazard ratio [HR]=1.01, P=0.025), along with age, sex, albumin and platelet count. Standardized spleen volume (HR=1.01, P<0.001) and VAT index (HR=0.98, P=0.004) were significantly associated with hepatic decompensation along with age and albumin. Furthermore, VAT index (HR=1.01, P=0.001) and standardized spleen volume (HR=1.01, P=0.001) were significant predictors for DM, along with sex, age, and albumin. SAT index (HR=0.99, P=0.004) was significantly associated with OS, along with age, albumin, and MELD.

          Conclusions

          Deep learning-based automatically measured spleen volume, VAT, and SAT indices may provide various prognostic information in patients with CHB.

          Related collections

          Most cited references48

          • Record: found
          • Abstract: not found
          • Article: not found

          EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma

            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.

            Hepatitis B virus (HBV) infection remains a global public health problem with changing epidemiology due to several factors including vaccination policies and migration. This Clinical Practice Guideline presents updated recommendations for the optimal management of HBV infection. Chronic HBV infection can be classified into five phases: (I) HBeAg-positive chronic infection, (II) HBeAg-positive chronic hepatitis, (III) HBeAg-negative chronic infection, (IV) HBeAg-negative chronic hepatitis and (V) HBsAg-negative phase. All patients with chronic HBV infection are at increased risk of progression to cirrhosis and hepatocellular carcinoma (HCC), depending on host and viral factors. The main goal of therapy is to improve survival and quality of life by preventing disease progression, and consequently HCC development. The induction of long-term suppression of HBV replication represents the main endpoint of current treatment strategies, while HBsAg loss is an optimal endpoint. The typical indication for treatment requires HBV DNA >2,000IU/ml, elevated ALT and/or at least moderate histological lesions, while all cirrhotic patients with detectable HBV DNA should be treated. Additional indications include the prevention of mother to child transmission in pregnant women with high viremia and prevention of HBV reactivation in patients requiring immunosuppression or chemotherapy. The long-term administration of a potent nucleos(t)ide analogue with high barrier to resistance, i.e., entecavir, tenofovir disoproxil or tenofovir alafenamide, represents the treatment of choice. Pegylated interferon-alfa treatment can also be considered in mild to moderate chronic hepatitis B patients. Combination therapies are not generally recommended. All treated and untreated patients should be monitored for treatment response and adherence, and the risk of progression and development of complications. HCC remains the major concern for treated chronic hepatitis B patients. Several subgroups of patients with HBV infection require specific focus. Future treatment strategies to achieve 'cure' of disease and new biomarkers are discussed.
              Bookmark
              • Record: found
              • Abstract: not found
              • Article: not found

              Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance.

                Bookmark

                Author and article information

                Journal
                Clin Mol Hepatol
                Clin Mol Hepatol
                CMH
                Clinical and Molecular Hepatology
                The Korean Association for the Study of the Liver
                2287-2728
                2287-285X
                October 2023
                29 August 2023
                : 29
                : 4
                : 1029-1042
                Affiliations
                [1 ]Department of Radiology, Seoul National University Hospital, Seoul, Korea
                [2 ]Department of Internal Medicine and Liver Research Institute, Seoul National University College of Medicine, Seoul, Korea
                [3 ]Department of Radiology, Seoul National University College of Medicine, Seoul, Korea
                [4 ]Institute of Radiation Medicine, Seoul National University Medical Research Center, Seoul, Korea
                Author notes
                Corresponding author : Dong Ho Lee Department of Radiology, Seoul National University Hospital, 101 Daehak-ro, Jongno-gu, Seoul 03080, Korea Tel: +82-2-2072-2584; Fax: +82-2-743-6385, E-mail: dhlee.rad@ 123456gmail.com
                [*]

                J Yoo and H Cho contributed equally as co-first authors.

                Editor: Yong Eun Chung, Yonsei University College of Medicine, Korea

                Author information
                http://orcid.org/0000-0001-8983-851X
                Article
                cmh-2023-0190
                10.3350/cmh.2023.0190
                10577347
                37822214
                50e38dd5-1b69-4f4f-a05f-5b8ce4d1fc89
                Copyright © 2023 by The Korean Association for the Study of the Liver

                This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

                History
                : 1 June 2023
                : 8 August 2023
                : 27 August 2023
                Categories
                Original Article

                Gastroenterology & Hepatology
                chronic hepatitis b,hepatocellular carcinoma,liver cirrhosis,diabetes mellitus,survival

                Comments

                Comment on this article

                scite_

                Similar content34

                Cited by4

                Most referenced authors870